[血管紧张素转换酶抑制剂诱发的血管性水肿]

[ACE-inhibitor induced angioedema].

作者信息

Bas M, Hoffmann T K, Kojda G, Bier H

机构信息

Hals-Nasen-Ohrenklinik und Poliklinik, Klinikum rechts der Isar der Technischen Universität München, München, Germany.

出版信息

Laryngorhinootologie. 2007 Nov;86(11):804-8, quiz 809-13. doi: 10.1055/s-2007-966932.

DOI:10.1055/s-2007-966932

PMID:17966084

Abstract

ACE-inhibitor induced angioedema is a non-allergic drug-related side effect. Inhibited bradykinin degradation leads to an unphysiological enhanced bradykinin plasma level with vascular leakage and, consequently, to angioedema. ACE-inhibitor induced angioedema develop rapidly in the head and neck region. Typical sites of manifestation are lips, tongue, and larynx. Novel pharmacotherapies may allow a causal treatment of the ACE-inhibitor induced angioedema in the future.

摘要

血管紧张素转换酶抑制剂（ACEI）诱导的血管性水肿是一种与药物相关的非过敏性副作用。缓激肽降解受抑制会导致血浆缓激肽水平异常升高，进而引发血管渗漏，最终导致血管性水肿。ACEI诱导的血管性水肿在头颈部迅速发展。典型的表现部位是嘴唇、舌头和喉部。新型药物疗法可能在未来实现对ACEI诱导的血管性水肿的病因治疗。